5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
ViroGates AS's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 249.42%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ViroGates AS's 5-Year ROIIC % or its related term are showing as below:
FRA:EP2's 5-Year ROIIC % is ranked better than 94.82% of 734
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs FRA:EP2: 249.42
ViroGates AS (FRA:EP2) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ViroGates AS 5-Year ROIIC % Related Terms
ViroGates AS 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ViroGates AS's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EP2 vs ABT, SYK, MDT: 5-Year ROIIC % Comparison
For the Medical Devices subindustry, ViroGates AS's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS 5-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ViroGates AS's 5-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ViroGates AS (FRA:EP2) has a 5-Year ROIIC % of 249.42 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #38 out of 734 companies in the Medical Devices & Instruments industry, placing it in the top 5.2%.
Is ViroGates AS's 5-Year ROIIC % too high?
ViroGates AS's current 5-Year ROIIC % is 249.42. The Medical Devices & Instruments industry median 5-Year ROIIC % is 0.95. ViroGates AS's value of 249.42 is 26154.7% above this industry median. Based on the distribution chart, ViroGates AS ranks #38 out of 734 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ViroGates AS has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's 5-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #38 out of 734 companies for 5-Year ROIIC %. This places ViroGates AS in the top 5% of its industry — outperforming the majority of peers. The industry median 5-Year ROIIC % is 0.95. ViroGates AS's value of 249.42 is 26154.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Devices & Instruments company?
The median 5-Year ROIIC % among Medical Devices & Instruments companies is 0.95, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ViroGates AS's current 5-Year ROIIC % of 249.42 is 26154.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median 5-Year ROIIC % is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current 5-Year ROIIC % is 249.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
ViroGates AS (FRA:EP2) has a current 5-Year ROIIC % of 249.42. The stock's GF Value™ is €0.90, compared to a current price of €1.45 — trading 61.1% above its estimated fair value. The current 5-Year ROIIC % is 249.42 and 26154.7% above the Medical Devices & Instruments industry median of 0.95. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current 5-Year ROIIC % is 249.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (FRA:EP2) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of €1.45 is trading 61.1% above its estimated GF Value™ of €0.90.
Key valuation signals for FRA:EP2:
5-Year ROIIC %: 249.42
GF Value™: €0.90 vs. price of €1.45 (61.1% above fair value)
Industry Position: 26154.7% above the Medical Devices & Instruments median (#38 of 734)
No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score
Get the complete analysis for FRA:EP2
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EP2 has been successfully added to your 
